How much more can you learn from every screening plate? In this joint webinar, Roberto Ravasio (Principal Scientist, Axxam) and Riccardo Dainese (CBO and co-founder, Alithea Genomics) show how Cell Painting and MERCURIUS™ DRUG-seq work together across the drug discovery workflow, with real data from two case studies.
Case study 1 – Target validation in human iPSC-derived motor neurons
An arrayed CRISPR screen of 90 ALS-relevant targets under arsenite stress, profiled with Cell Painting and DRUG-seq. Integrating both readouts at target level puts SMARCA4 and HDAC6 among the top candidates for follow-up.
Case study 2 – Which readout flags liver toxicity first?
58 drugs from the FDA DILIrank dataset, 8 doses each, in HepaRG and U2OS cells: 2,160 samples per readout and cell model. DRUG-seq names the mechanism (DNA damage, mitochondrial stress) and Cell Painting shows its effect on the cell.
What you will learn
- Where Cell Painting and transcriptomics fit from target identification to safety
- How two readouts on the same plates build a stronger case for each target
- How DRUG-seq pinpoints the mechanism and the dose at which it switches on
- How gene-level benchmark dose modelling detects activation at lower doses
Chapters
0:00 Welcome and speakers
0:50 Agenda
1:33 Why combine readouts? Better perturbation data for AI-driven drug discovery
3:29 Alithea Genomics and MERCURIUS™ DRUG-seq
7:07 Axxam: science-driven drug discovery
9:43 Cell Painting + DRUG-seq: one workflow, two readouts
11:53 Case study 1: target validation in iPSC-derived motor neurons (ALS)
18:26 Cell Painting results: six phenotypic programs
22:40 Adding DRUG-seq: ALS-relevant transcriptional programs
24:48 Integrated target prioritization: SMARCA4 and HDAC6
30:34 Case study 2: which readout flags liver toxicity first?
32:05 Point of departure: Cell Painting vs DRUG-seq
35:53 Mechanisms: DNA damage and mitochondrial toxicity
38:56 Glitazones: shared target, distinct phenotypes
41:41 Benchmark dose modelling with DRUG-seq
43:29 Takeaways
45:27 Q&A: comparison with the JUMP Consortium
47:30 Q&A: Cell Painting image analysis at Axxam
48:58 Q&A: knockout efficiency in iPSC-derived neurons
50:24 Q&A: estimating a therapeutic window
53:42 Q&A: recovering mechanisms of action
55:42 Q&A: how many cell types for toxicity screening?